Supported by clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeutics is expanding into a second autoimmune indication, Sjögren’s Disease (SjD)
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, announced it will be initiating clinical evaluation of R-2487 in SjD.
The new SJD study will be funded by the National Institute of Dental and Craniofacial Research (NIDCR) and builds on emerging clinical and biomarker data from Rise’s ongoing clinical trial of R-2487 in RA.
R-2487 is a first-in-class targeted immune modulator delivered orally to induce tolerogenic dendritic cells, promoting immune homeostasis and peripheral tolerance, mechanisms known to be dysregulated in rheumatologic diseases.
Read more about Rise Therapeutics Secures New Funding To Advance First-in-Class R-2487 Oral Immune Biomodulator Into Sjogren’s Disease Clinical Testing.
